The US FDA exercised regulatory flexibility on Eisai Co., Ltd. and Biogen, Inc.’s Leqembi (lecanemab-irmb) in its evaluation of clinical efficacy data, and the size of the safety database, for the Alzheimer’s disease drug.
The drug failed to meet the prespecified clinical endpoint in a Phase II trial. However, since it was following the...